IMMUNIC, INC. 8-K

What Happened Immunic, Inc. (IMUX) filed a Form 8-K on May 28, 2026, disclosing a press release and presentation about new data from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU‑838), a Nurr1 activator, in patients with progressive multiple sclerosis (PMS). The company presented one late‑breaking abstract and two additional posters at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 27–29, 2026, in Charlotte, North Carolina, and posted the presentation on its website on May 28, 2026.

Key Details

• Filing date: Form 8‑K filed May 28, 2026 (Regulation FD disclosure).
• Presentation: one late‑breaking poster plus two additional posters summarizing additional CALLIPER Phase 2 data.
• Drug/program: vidofludimus calcium (IMU‑838), described as a nuclear receptor‑related 1 (Nurr1) activator, being studied in progressive multiple sclerosis.
• Event: 2026 CMSC Annual Meeting, May 27–29, 2026, Charlotte, NC; press release and presentation attached to the 8‑K.

Why It Matters Clinical data presentations provide transparency on drug development progress and can influence investor interest and clinical partner engagement. By issuing a press release, presenting late‑breaking and additional posters at a major MS conference, and posting the materials publicly, Immunic is updating the market on new Phase 2 findings for its lead asset, vidofludimus calcium—information that investors and analysts will use to assess the program’s development trajectory.